| Literature DB >> 30050662 |
Xue Wang1, Yidi Qu1, Yongfeng Zhang1, Shaopeng Li1,2, Yiyang Sun1, Zepeng Chen1, Lirong Teng1,2, Di Wang1,2.
Abstract
Sarcodon imbricatus (SI), a precious edible fungus, contains 35.22% of total sugar, 18.33% of total protein, 24 types of fatty acid, 16 types of amino acid, and 8 types of minerals. Encouragingly, it is rich in potential antioxidants such as total polyphenols (0.41%), total sterols (3.16%), and vitamins (0.44%). In the present study, the antifatigue properties of SI and its potential mechanisms of action were explored by the experiments on acute excise-treated mice and chronic fatigue syndrome (CFS) mice. SI (0.25, 0.5, and 1 g/kg) significantly enhanced exercise tolerance in the weight-loaded forced swimming test (FST) and rota-rod test (RRT) and reduced the immobility in the tail suspension test on CFS mice. SI markedly increased the levels of glycogen in the liver and adenosine triphosphate (ATP) in the liver and muscle and decreased the lactic acid (LD) and blood urea nitrogen (BUN) content in both acute swimming-treated mice and CFS mice. SI improved the endogenous cellular antioxidant enzyme contents in the two mouse models by improving the activities of superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) and reducing reactive oxygen species (ROS) and malondialdehyde (MDA) levels in serum, liver, and muscle, respectively. In CFS mice, the enhanced expression levels of nuclear factor erythroid-2-related factor 2 (Nrf2), SOD1, SOD2, heme oxygenase-1 (HO-1), and catalase (CAT) in the liver were observed after a 32-day SI administration. Our data indicated that SI possessed antifatigue activity, which may be related to its ability to normalize energy metabolism and Nrf2-mediated oxidative stress. Consequently, SI can be expected to serve as a novel natural antifatigue supplement in health foods.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30050662 PMCID: PMC6046126 DOI: 10.1155/2018/9140896
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 6.543
Figure 1(a) The experimental protocol and drug administration procedure on acute exercise-treated mice. The effects of SI and GS on (b) weight-loaded forced swimming test and (c) rota-rod test in normal mice. Data were analyzed using a one-way ANOVA followed by Dunn's test and expressed as means ± SD (n = 10). #P < 0.05 and ##P < 0.01 versus the control group. SI: S. imbricatus; GS: Ginsenoside.
Figure 2(a) The experimental protocol and drug administration procedure on CFS mice. The effects of SI and GS on (b) weight-loaded forced swimming test, (c) rota-rod test, and (d) tail suspension test in CFS mice. Data were analyzed using a one-way ANOVA followed by Dunn's test and expressed as means ± SD (n = 10). ###P < 0.001 versus the control group; ∗P < 0.05 and ∗∗P < 0.01 versus the model group. SI: S. imbricatus; GS: Ginsenoside.
Main components of SI.
| Compounds | Contents (%) | Compounds | Contents (%) | Compounds | Contents (%) |
|---|---|---|---|---|---|
| Total sugar | 35.22 | Mannitol | 9.40 | Polyphenols | 0.41 |
| Reducing sugar | 3.41 | Crude fat | 3.02 | Carotenoids (×10−3) | 0.21 |
| Triterpenoids (×10−2) | 4.12 | Total ash | 9.30 | Sterols | 3.16 |
| Flavonoids (×10−2) | 2.05 | Total protein | 18.33 |
SI: Sarcodon imbricatus
The composition of vitamins in SI.
| Compounds | Contents (mg/kg) | Compounds | Contents (mg/kg) | Compounds | Contents (mg/kg) |
|---|---|---|---|---|---|
| Vitamin A | 0.12 | Vitamin B3 (×103) | 3.16 | Vitamin D2 (×102) | 1.10 |
| Vitamin B1 | ND① | Vitamin B6 | ND② | Vitamin D3 | ND③ |
| Vitamin B2 | 28.68 | Vitamin C (×103) | 1.06 | Vitamin E | ND④ |
SI: Sarcodon imbricatus; ND①: not detected (the detection limit was 0.54 mg/kg); ND②: not detected (the detection limit was 2.92 mg/kg); ND③: not detected (the detection limit was 0.08 mg/kg); ND④: not detected (the detection limit was 1.32 mg/kg).
The composition of fatty acids.
| Compounds | Contents (‰) | Compounds | Contents (‰) | Compounds | Contents (‰) |
|---|---|---|---|---|---|
| Octoic acid (C8:0) | ND① | Heptadecenoic acid (C17:1) (×10−2) | 3.02 | Docosanoic acid (C22:0) (×10−2) | 8.30 |
| Capric acid (C10:0) | ND② | Stearic acid (C18:0) (×10−1) | 4.70 | Eicosatrienoic acid (C20:3n6) | ND⑦ |
| Undecanoic acid (C11:0) (×10−2) | 0.51 | Trans-oleic acid (C18:1n9t) (×10−2) | 3.61 | Erucic acid (C22:1n9) | ND⑧ |
| Lauric acid (C12:0) (×10−2) | 1.72 | Oleic acid (C18:1n9c) | 4.89 | Eicosatrienoic acid (C20:3n3) (×10−2) | 1.92 |
| Tridecanoic acid (C13:0) (×10−2) | 0.40 |
| 0.62 | Arachidonic acid (C20:4n6) | ND⑨ |
| Myristic acid (C14:0) | 0.07 | Linoleic acid (C18:2n6c) | 15.26 | Tricosanoic acid (C23:0) (×10−2) | 1.32 |
| Myristoleic acid (C14:1) | ND③ | Arachidic acid (C20:0) (×10−2) | 4.43 | Docosadienoic acid (C22:2n6) (×10−2) | 2.20 |
| Pentadecanoic acid (C15:0) | 0.72 |
| ND⑤ | Tetracosanoic acid (C24:0) (×10−2) | 5.12 |
| Pentadecenoic acid (C15:1) | ND④ | Eicosanoic acid (C20:1n9) | ND⑥ | Eicosapentaenoic acid (C20:5n3) | ND⑩ |
| Hexadecanoic acid (C16:0) | 1.97 |
| 5.34 | Nervonic acid (C24:1n9) (×10−1) | 0.05 |
| Palmitoleic acid (C16:1) | 0.07 | Heneicosanoic acid (C21:0) (×10−2) | 0.41 | Docosahexaenoic acid (C22:6n3) | ND⑪ |
| Heptadecanoic acid (C17:0) | 0.07 | Eicosadienoic acid (C20:2) | 0.04 |
ND①: not detected (the detection limit was 4.20 mg/kg); ND②: not detected (the detection limit was 3.83 mg/kg); ND③: not detected (the detection limit was 2.82 mg/kg); ND④: not detected (the detection limit was 2.64 mg/kg); ND⑤: not detected (the detection limit was 2.51 mg/kg); ND⑥: not detected (the detection limit was 4.77 mg/kg); ND⑦: not detected (the detection limit was 2.68 mg/kg); ND⑧: not detected (the detection limit was 2.42 mg/kg); ND⑨: not detected (the detection limit was 4.66 mg/kg); ND⑩: not detected (the detection limit was 3.31 mg/kg); ND⑪: not detected (the detection limit was 4.33 mg/kg).
The composition of amino acids in SI.
| Compounds | Contents (%) | Compounds | Contents (%) | Compounds | Contents (%) |
|---|---|---|---|---|---|
| Aspartic acid (Asp) | 1.11 | Valine (Val) | 0.62 | Lysine (Lys) | 0.61 |
| L-Threonine (Thr) | 0.64 | DL-Methionine (Met) | 0.40 | Histidine (His) | 0.10 |
| Serine (Ser) | 0.38 | Isoleucine (Iso) | 0.56 | Arginine (Arg) | 0.60 |
| Glutamic acid (Glu) | 3.04 | Leucine (Leu) | 0.88 | Proline (Pro) | 0.54 |
| Glycine (Gly) | 0.45 | Tyrosine (Tyr) | 0.34 | ||
| Alanine (Ala) | 1.10 | Phenylalanine (Phe) | 0.54 |
SI: Sarcodon imbricatus
The composition of minerals (including heavy metals) in SI.
| Compounds | Contents (mg/100 g) | Compounds | Contents (mg/kg) |
|---|---|---|---|
| Kalium (K) (×102) | 39.57 | Selenium (Se) | ND① |
| Natrium (Na) | 14.52 | Lead (Pb) | ND② |
| Calcium (Ca) | 68.04 | Mercury (Hg) | ND③ |
| Cuprum (Cu) | 3.31 | Arsenic (As) | ND④ |
| Ferrum (Fe) | 78.42 | Cadmium (Cd) | ND⑤ |
| Zinc (Zn) | 10.92 | Chromium (Cr) | ND⑥ |
| Manganese (Mn) | 3.30 |
SI: Sarcodon imbricatus; ND①: not detected (the detection limit was 2 mg/kg); ND②: not detected (the detection limit was 1 mg/kg); ND③: not detected (the detection limit was 0.1 mg/kg); ND④: not detected (the detection limit was 0.5 mg/kg); ND⑤: not detected (the detection limit was 0.5 mg/kg); ND⑥: not detected (the detection limit was 1 mg/kg).
Figure 3Mice were treated with SI (0.25, 0.5, and 1.0 g/kg) and GS (0.05 g/kg) for 18 days. After a 30 min swimming, the levels of (a) BUN and LD in serum, (b) ATP, and (c) glycogen in the liver and muscle were detected via ELISA kit. CFS mice were treated with SI (0.25, 0.5, and 1.0 g/kg) and GS (0.05 g/kg) for 32 days. The levels of (d) BUN and LD in serum, (e) ATP, and (f) glycogen in the liver and muscle were detected via ELISA kit. Data were analyzed using a one-way ANOVA followed by Dunn's test and expressed as means ± SD (n = 10). #P < 0.05 and ##P < 0.01 versus the control group; ∗P < 0.05 and ∗∗P < 0.01 versus the model group. SI: S. imbricatus; GS: Ginsenoside.
The effects of SI on oxidative stress-related factors in serum, liver, and muscle of acute excise-treated mice.
| CTRL | SI (g/kg) | GS (g/kg) | ||||
|---|---|---|---|---|---|---|
| 0.25 | 0.5 | 1 | 0.05 | |||
| Serum | MDA (nmol/mL) | 8.4 ± 2.0 | 8.0 ± 1.4 | 7.9 ± 2.2 | 6.9 ± 1.3# | 6.7 ± 1.7# |
| ROS (U/mL) | 461.0 ± 20.0 | 442.6 ± 21.9 | 401.6 ± 17.8## | 415.4 ± 28.6# | 381.9 ± 11.9## | |
| SOD (U/mL) | 74.5 ± 12.0 | 83.6 ± 5.7 | 85.8 ± 11.0# | 86.3 ± 13.0# | 85.1 ± 8.8# | |
| GSH-Px (U/mL) | 418.4 ± 90.8 | 518.2 ± 170.1# | 539.2 ± 156.8# | 559.2 ± 38.7## | 568.8 ± 97.4## | |
|
| ||||||
| Liver | MDA (nmol/mgprot) | 5.2 ± 0.7 | 4.4 ± 0.3# | 4.8 ± 0.3 | 3.7 ± 0.4## | 4.6 ± 0.5# |
| ROS (FI/gprot) | 22103.5 ± 7400.4 | 25042.9 ± 9027.8 | 17296.6 ± 1974.0# | 14914.6 ± 4638.8## | 18780.5 ± 5160.0# | |
| SOD (U/mgprot) | 234.9 ± 48.8 | 273.3 ± 49.8 | 340.7 ± 91.8## | 256.3 ± 49.3 | 343.1 ± 49.4## | |
| GSH-Px ( | 780.0 ± 195.0 | 818.3 ± 84.9 | 856.3 ± 19.4# | 790.8 ± 85.1 | 886.2 ± 140.6# | |
|
| ||||||
| Muscle | MDA (nmol/mgprot) | 23.7 ± 4.6 | 24.2 ± 2.2 | 22.7 ± 2.2 | 21.6 ± 2.7 | 22.3 ± 2.1 |
| ROS (FI/gprot) | 61278.3 ± 8914.2 | 59534.4 ± 4636.2 | 53426.1 ± 333.9# | 51847.6 ± 5748.2# | 47689.1 ± 6061.2## | |
| SOD (U/mgprot) | 115.5 ± 23.4 | 122.4 ± 30.3 | 187.3 ± 24.6## | 179.6 ± 19.4# | 204.5 ± 29.7## | |
| GSH-Px ( | 653.9 ± 75.4 | 663.3 ± 43.1 | 702.4 ± 32.8 | 660.9 ± 46.8 | 756.2 ± 65.9# | |
Treatment with SI (0.25 g/kg, 0.5 g/kg, and 1.0 g/kg) and GS (0.05 g/kg) for 18 days; after a 30 min swimming, the levels of MDA and ROS and the activities of SOD and GSH-Px in serum, liver, and muscle were detected. The data were analyzed using a one-way ANOVA followed by Dunn's test and expressed as means ± SD (n = 10/group). #P < 0.05 and ##P < 0.01 versus the control group. SI: S. imbricatus; GS: Ginsenoside.
The effects of SI on oxidative stress-related factors in serum, liver, and muscle of CFS mice.
| CTRL | Model | SI (g/kg) | GS (g/kg) | ||||
|---|---|---|---|---|---|---|---|
| 0.25 | 0.5 | 1 | 0.05 | ||||
| Serum | MDA (nmol/mL) | 22.4 ± 2.6 | 28.2 ± 1.5# | 21.8 ± 3.0 | 20.2 ± 1.4∗∗ | 22.1 ± 0.9 | 19.9 ± 1.2∗∗ |
| ROS (U/mL) | 203.3 ± 19.4 | 263.1 ± 9.0# | 237.3 ± 15.1 | 232.5 ± 21.2∗ | 221.7 ± 16.8∗ | 224.4 ± 23.5∗ | |
| SOD (U/mL) | 158.2 ± 11.2 | 129.7 ± 7.6# | 137.6 ± 8.7 | 139.7 ± 11.9 | 154.8 ± 23.6∗ | 142.2 ± 21.1∗ | |
| GSH-Px (U/mL) | 230.4 ± 29.8 | 192.0 ± 15.5# | 209.2 ± 27.0 | 203.5 ± 19.8 | 218.7 ± 21.2∗ | 220.8 ± 10.6∗ | |
|
| |||||||
| Liver | MDA (nmol/mgprot) | 4.5 ± 0.5 | 5.6 ± 0.7# | 5.3 ± 1.3 | 5.5 ± 0.7 | 4.5 ± 0.9∗ | 4.5 ± 0.6∗ |
| ROS (U/mgprot) | 384.8 ± 41.6 | 449.2 ± 9.4# | 420.3 ± 29.6 | 372.2 ± 39.8∗ | 379.1 ± 29.7∗ | 358.7 ± 20.2∗∗ | |
| SOD (U/mgprot) | 136.1 ± 12.2 | 105.4 ± 8.2## | 125.3 ± 25.1 | 128.5 ± 24.5∗ | 120.4 ± 30.2 | 136.9 ± 23.9∗ | |
| GSH-Px (U/mgprot) | 172.7 ± 13.6 | 110.5 ± 13.2## | 163.9 ± 23.5∗ | 169.5 ± 24.5∗ | 157.6 ± 16.8 | 168.2 ± 27.4∗ | |
|
| |||||||
| Muscle | MDA (nmol/mgprot) | 6.1 ± 1.2 | 7.5 ± 1.1# | 6.7 ± 1.2 | 6.3 ± 1.4 | 6.1 ± 0.7 | 6.0 ± 0.8∗ |
| ROS (U/mgprot) | 336.5 ± 39.8 | 402.2 ± 26.8## | 423.2 ± 34.2 | 358.0 ± 37.9∗∗ | 369.7 ± 38.0∗ | 349.6 ± 36.2∗∗ | |
| SOD (U/mgprot) | 289.6 ± 48.6 | 210.2 ± 19.8# | 277.7 ± 35.4 | 297.2 ± 66.7∗ | 311.1 ± 29.7∗∗ | 287.9 ± 42.9∗ | |
| GSH-Px (U/mgprot) | 167.7 ± 61.7 | 150.6 ± 30.7# | 160.0 ± 47.1 | 170.5 ± 33.2∗ | 165.2 ± 48.1 | 174.0 ± 47.3∗ | |
Treatment with SI (0.25 g/kg, 0.5 g/kg, and 1.0 g/kg) and GS (0.05 g/kg) for 32 days in CFS mice; the levels of MDA and ROS and the activities of SOD and GSH-Px in serum, liver, and muscle were detected. The data were analyzed using a one-way ANOVA followed by Dunn's test and expressed as means ± SD (n = 10/group). #P < 0.05 and ##P < 0.01 versus the control group; ∗P < 0.05 and ∗∗P < 0.01 versus the model group. SI: S. imbricatus; GS Ginsenoside.
Figure 4CFS mice were treated with SI (0.25, 0.5, and 1.0 g/kg) and GS (0.05 g/kg) for 32 days. The expression levels of Nrf2, SOD1, SOD2, HO-1, and CAT in the liver were detected via Western blot. Quantification data were normalized by related GAPDH and expressed as means ± SD (n = 10). #P < 0.05 and ##P < 0.01 versus the control group. ∗P < 0.05, ∗∗P < 0.01, and ∗∗∗P < 0.001 versus the model group. SI: S. imbricatus; GS: Ginsenoside.